Equities research analysts predict that Spero Therapeutics Inc (NASDAQ:SPRO) will announce sales of $3.54 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Spero Therapeutics’ earnings, with estimates ranging from $2.00 million to $5.37 million. Spero Therapeutics reported sales of $1.69 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 109.5%. The company is scheduled to report its next earnings report on Thursday, March 12th.

According to Zacks, analysts expect that Spero Therapeutics will report full-year sales of $18.05 million for the current fiscal year, with estimates ranging from $16.50 million to $19.89 million. For the next financial year, analysts expect that the company will post sales of $14.12 million, with estimates ranging from $8.40 million to $19.25 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Monday, November 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.10). The business had revenue of $4.64 million during the quarter, compared to analysts’ expectations of $2.03 million. Spero Therapeutics had a negative net margin of 287.11% and a negative return on equity of 43.10%.

SPRO has been the subject of a number of research analyst reports. Zacks Investment Research lowered Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 12th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Spero Therapeutics in a report on Wednesday. Cowen restated a “buy” rating on shares of Spero Therapeutics in a report on Tuesday, November 5th. Janney Montgomery Scott initiated coverage on Spero Therapeutics in a report on Monday, September 9th. They issued a “buy” rating for the company. Finally, Oppenheimer reduced their target price on Spero Therapeutics from $30.00 to $20.00 in a report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $23.50.

Shares of SPRO traded up $0.17 during mid-day trading on Monday, reaching $11.09. The company’s stock had a trading volume of 59,684 shares, compared to its average volume of 48,266. The business has a fifty day moving average of $10.99 and a 200 day moving average of $10.85. The company has a market cap of $210.60 million, a price-to-earnings ratio of -4.27 and a beta of 2.10. Spero Therapeutics has a 1 year low of $5.52 and a 1 year high of $14.48. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.04.

Several hedge funds and other institutional investors have recently bought and sold shares of SPRO. Novo Holdings A S acquired a new position in shares of Spero Therapeutics in the second quarter worth $5,363,000. BlackRock Inc. increased its stake in shares of Spero Therapeutics by 56.0% in the second quarter. BlackRock Inc. now owns 656,778 shares of the company’s stock worth $7,559,000 after acquiring an additional 235,691 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Spero Therapeutics by 89.7% in the second quarter. Renaissance Technologies LLC now owns 214,903 shares of the company’s stock worth $2,474,000 after acquiring an additional 101,600 shares during the last quarter. AWM Investment Company Inc. increased its stake in shares of Spero Therapeutics by 6.4% in the second quarter. AWM Investment Company Inc. now owns 598,315 shares of the company’s stock worth $6,887,000 after acquiring an additional 36,019 shares during the last quarter. Finally, State Street Corp increased its position in Spero Therapeutics by 16.3% during the third quarter. State Street Corp now owns 197,226 shares of the company’s stock worth $2,091,000 after buying an additional 27,695 shares during the last quarter. 48.36% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

See Also: Treasury Bonds

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.